A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa

Inclusion Criteria: * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and including 6 and 10 weeks of age at the time of the first vaccination. * Written informed consent obtained from the parents or guardians of the subject * Documented HIV status of the subject as confirmed by PCR. * HIV asymptomatic and HIV mildly symptomatic; Stages I and II disease according to WHO's most recent classification for HIV stages in infants and children. * Born after a gestation period of 36 to 42 weeks. Exclusion Criteria: * Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Previous routine vaccination except OPV, BCG and HBV vaccination at birth * Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract or other serious medical condition as determined by the investigator. * History of allergic disease or reaction likely to be exacerbated by any component of the vaccine. * Acute disease at time of enrolment. * Gastroenteritis within 7 days preceding the study vaccine administration. * Previous confirmed occurrence of RV gastroenteritis. * Other conditions which in the opinion of the investigator may potentially interfere with interpr…